These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 19728395)

  • 1. Severe pulmonary complications after bortezomib treatment in multiple myeloma.
    Dun X; Yuan Z; Fu W; Zhang C; Hou J
    Hematol Oncol; 2010 Mar; 28(1):49-52. PubMed ID: 19728395
    [No Abstract]   [Full Text] [Related]  

  • 2. Severe pulmonary complications after bortezomib treatment for multiple myeloma: an unrecognized pulmonary vasculitis?
    Pitini V; Arrigo C; Altavilla G; Naro C
    Leuk Res; 2007 Jul; 31(7):1027-8. PubMed ID: 17134751
    [No Abstract]   [Full Text] [Related]  

  • 3. Pulmonary fibrosis in a myeloma patient on bortezomib treatment. A new severe adverse effect of a new drug.
    Duek A; Feldberg E; Haran M; Berrebi A
    Am J Hematol; 2007 Jun; 82(6):502-3. PubMed ID: 17301973
    [No Abstract]   [Full Text] [Related]  

  • 4. Severe epidermal necrolysis after bortezomib treatment for multiple myeloma.
    Fang B; Song Y; Ma J; Zhao RC
    Acta Haematol; 2007; 118(2):65-7. PubMed ID: 17505132
    [No Abstract]   [Full Text] [Related]  

  • 5. Bortezomib increases survival of patients with relapsed multiple myeloma.
    Health News; 2005 Sep; 11(9):9. PubMed ID: 16211682
    [No Abstract]   [Full Text] [Related]  

  • 6. [Safety evaluation of bortezomib in multiple myeloma patients with severe renal failure].
    Muta T; Nakanishi H; Yasunaga M; Senba S; Murakami H; Kan S; Ueda Y; Fujisaki T
    Gan To Kagaku Ryoho; 2011 Feb; 38(2):237-41. PubMed ID: 21368487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bortezomib-induced acute pancreatitis.
    Elouni B; Ben Salem C; Zamy M; Sakhri J; Bouraoui K; Biour M
    JOP; 2010 May; 11(3):275-6. PubMed ID: 20442528
    [No Abstract]   [Full Text] [Related]  

  • 8. Hyperlipidemia in a myeloma patient after bortezomib treatment.
    Gozzetti A; Fabbri A; Defina M; Chitarrelli I; Bocchia M
    Leuk Res; 2010 Sep; 34(9):e250. PubMed ID: 20363499
    [No Abstract]   [Full Text] [Related]  

  • 9. Deafness associated with the use of Bortezomib in multiple myeloma.
    Chim CS; Wong LG
    Acta Oncol; 2008; 47(2):323-4. PubMed ID: 17851876
    [No Abstract]   [Full Text] [Related]  

  • 10. Bortezomib-induced Sweet syndrome.
    Knoops L; Jacquemain A; Tennstedt D; Theate I; Ferrant A; Van den Neste E
    Br J Haematol; 2005 Oct; 131(2):142. PubMed ID: 16197442
    [No Abstract]   [Full Text] [Related]  

  • 11. Clinical assessment of bortezomib for multiple myeloma in comparison with thalidomide.
    Satoh M; Oguro R; Yamanaka C; Takada K; Matsuura Y; Akiba T; Aotsuka N; Tani Y; Wakita H
    J Pharm Pharm Sci; 2011; 14(1):78-89. PubMed ID: 21501555
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pseudomembranous colitis following bortezomib therapy in a myeloma patient.
    Moon SJ; Min CK; Lee DG; Lee S; Lee JW; Min WS; Kim CC; Kim M; Park G; Kim Y
    Acta Haematol; 2007; 117(4):211-4. PubMed ID: 17237615
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bortezomib-induced skin eruption.
    Sanchez-Politta S; Favet L; Kerl K; Dietrich PY; Piguet V
    Dermatology; 2008; 216(2):156-8. PubMed ID: 18216478
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bortezomib-induced perivascular dermatitis in a patient with multiple myeloma.
    Ozkurt ZN; Sucak GT; Aki SZ; Yağci M; Erdem O
    Cutan Ocul Toxicol; 2009; 28(3):141-3. PubMed ID: 19548772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug-induced hypersensitivity syndrome after bortezomib treatment for refractory multiple myeloma.
    Hattori N; Adachi D; Nakashima H; Saito B; Nakamaki T; Tomoyasu S
    Leuk Res; 2009 Apr; 33(4):574-7. PubMed ID: 18838167
    [No Abstract]   [Full Text] [Related]  

  • 16. From bench to bedside: a case of rapid reversal of bortezomib-induced neuropathic pain by the TRPM8 activator, menthol.
    Colvin LA; Johnson PR; Mitchell R; Fleetwood-Walker SM; Fallon M
    J Clin Oncol; 2008 Sep; 26(27):4519-20. PubMed ID: 18802169
    [No Abstract]   [Full Text] [Related]  

  • 17. Optimizing bortezomib treatment in patients with relapsed multiple myeloma.
    Richardson P
    Clin Adv Hematol Oncol; 2006 May; 4(5):4-5; discussion 8; suppl 13. PubMed ID: 16832859
    [No Abstract]   [Full Text] [Related]  

  • 18. Cutaneous lymphoid perivascular reaction with atypical CD30+ T cells in a patient with multiple myeloma treated with bortezomib.
    Dehesa L; Bastida J; Limeres-González M; Campos-Adsuar C; Gómez-Duaso J
    Clin Exp Dermatol; 2009 Dec; 34(8):e1031-2. PubMed ID: 20055832
    [No Abstract]   [Full Text] [Related]  

  • 19. The impact of bortezomib on the risk of thrombosis in multiple myeloma.
    Connolly G
    Leuk Res; 2011 Feb; 35(2):145-6. PubMed ID: 20952063
    [No Abstract]   [Full Text] [Related]  

  • 20. Bortezomib-induced severe hepatitis in multiple myeloma: a case report.
    Rosiñol L; Montoto S; Cibeira MT; Bladé J
    Arch Intern Med; 2005 Feb; 165(4):464-5. PubMed ID: 15738379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.